血常规相关指标检测对HCV感染相关肝炎、肝硬化及肝癌的临床诊断价值

doi:10.3969/j.issn.1671-7171.2025.10.012

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1241 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the auxiliary diagnostic value of routine blood test-related indicators in the progression of chronic liver diseases (hepatitis, cirrhosis, hepatocellular carcinoma) associated with hepatitis C virus (HCV) infection.【Methods】 A total of 215 patients with HCV infection were enrolled and divided into the hepatitis group (60 cases), the cirrhosis group (95 cases), and the hepatocellular carcinoma group (60 cases) according to disease stage. Differences in routine blood test-related indicators were compared among the three groups. Receiver operating characteristic (ROC) curves were used to evaluate the diagnostic efficacy of individual and combined indicators for disease staging.【Results】 Significant differences (all P<0.05) were observed among the three groups in platelet count (PLT), plateletcrit (PCT), lymphocyte count (L), neutrophil count (N), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-neutrophil ratio (PNR). The combined detection of L + PLT + PNR improved diagnostic performance in distinguishing hepatitis from cirrhosis, while N + PCT enhanced sensitivity in differentiating cirrhosis from hepatocellular carcinoma.【Conclusion】 Routine blood test-related indicators provide important reference value for staging diagnosis of HCV-associated liver diseases. Combined testing can optimize differential diagnosis of hepatitis, cirrhosis, and hepatocellular carcinoma in HCV-infected patients, offering a simple and cost-effective laboratory basis for clinical practice.

Key words： Hepacivirus Hepatitis Liver Cirrhosis Liver Neoplasms Diagnosis

Received: 17 June 2025

PACS:

R512.63

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Yang
	TANG Dongli

Cite this article:

LI Yang,TANG Dongli. Clinical Diagnostic Value of Routine Blood Test-Related Indicators in Hepatitis, Cirrhosis, and Hepatocellular Carcinoma Associated with HCV Infection[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(10): 1721-1724.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.10.012 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I10/1721

[1] 《原发性肝癌诊疗指南(2024年版)》编写专家委员会. 原发性肝癌诊疗指南(2024年版)[J].中国临床医学, 2024, 31(2):277.
[2] 中华医学会肝病学分会,中华医学会感染病学分会.丙型肝炎防治指南(2022年版)[J].中华传染病杂志,2023,41(1):29-46.
[3] ZHAO Z Y, CHU M J, GUO Y C, et al. Feasibility of hepatitis c elimination in China: from epidemiology, natural history, and intervention perspectives[J].Front Microbiol,2022, 13: 884598.
[4] MOUCHLI M, REDDY S, GERRARD M, et al. Usefulness of neutrophil-to-lymphocyte ratio (NLR) as a prognostic predictor after treatment of hepatocellular carcinoma[J].Ann Hepatol,2021,22:100249.
[5] 王煦众,罗朋立.血小板免疫功能与自身免疫性疾病的关系[J].中国医学创新,2024,21(30):172-177.
[6] 孟凡萱,崔久嵬.血小板:肿瘤诊断与治疗的新兴靶点[J].中国肿瘤生物治疗杂志,2023,30(1):10-19.
[7] ZANETTO A, CAMPELLO E, BULATO C, et al. Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death[J].J Hepatol,2022,77(3):660-669.
[8] 徐阳,刘莉君,王苗,等.丙型肝炎患者外周血常规散点图参数变化的研究[J].临床血液学杂志,2022,35(6):428-431.
[9] 王婧婧,韩振坤.慢性乙肝肝硬化分期及HBV-DNA载量对血小板减少的影响[J].实用中西医结合临床,2017,17(12):102-103.
[10] 张萌,李亚萍,贺娜,等.HCV感染肝癌背后的血小板[J].世界华人消化杂志,2024,32(10):735-741.
[11] 汪波,李阳,肖丽,等. 血小板压积对ALT小于2倍正常值上限慢性HBV感染者肝纤维化程度的预测价值分析[J].中华肝脏病杂志,2023,31(8):862-868.
[12] 杨娜,何华,赵天业,等.红细胞分布宽度/血小板比值、血小板/淋巴细胞比值、中性粒细胞/淋巴细胞比值对慢性丙型肝炎HCV感染肝硬化代偿期的预测价值[J].临床肝胆病杂志,2021,37(6):1319-1325.
[13] 覃元锋,石海燕,黄忠强.慢性丙型肝炎患者外周血淋巴细胞亚群的特征及临床意义[J].肝脏,2023,28(6):683-687.
[14] 李明政,王岩,王世明.免疫炎性细胞与HCV感染肝癌发生、发展及预后的关系[J].肿瘤研究与临床,2023,35(3):236-240.
[15] YANG D S, ZHOU Y, ZHANG Y B,et al. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq data reveals dynamic changes in tumor-associated neutrophils in the tumor microenvironment of hepatocellular carcinoma and leads to the establishment of a neutrophil-related prognostic model[J].Cancer Immunol Immunother,2023,72(12):4323-4335.

[1]	. [J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(9): 1624-1626.